OncClubAll Oncology News
InsightsMedNews WeekOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid Readouts
Conference CoverageConference Listing
Giants of Cancer CareCME/CEScientific InterchangesState of the Science Summit / IPCNational Fellows ForumWebinars
PartnersPublications
Consensus ViewpointsOncLive AppInteractive ToolsSponsored
Biomarker ConsortiumSubscribe
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
CAR T-cell Therapy
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Business Management
Pediatric Oncology
Precision Medicine in Oncology®
Sarcomas
Supportive Care
Spotlight -
  • The OncLive Insider app is live!
  • CME Opportunities
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
CAR T-cell Therapy
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Business Management
Pediatric Oncology
Precision Medicine in Oncology®
Sarcomas
Supportive Care
    • Partners
    • Publications
    • Biomarker Consortium
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Article

October 1, 2020

Brigatinib Boosts Intracranial PFS and Health-Related QoL in ALK+ NSCLC

Author(s):

Caroline Seymour
Conference|ESMO Congress

Brigatinib demonstrated sustained improvements in overall and intracranial progression-free survival and health-related quality of life compared with crizotinib in patients with ALK-positive advanced non–small cell lung cancer.

Brigatinib (Alunbrig) demonstrated sustained improvements in overall and intracranial progression-free survival (PFS) and health-related quality of life (HRQoL) compared with crizotinib (Xalkori) in patients with ALK-positive advanced non–small cell lung cancer (NSCLC), according to subgroup analyses from the phase 3 ALTA-1L trial that were presented at the 2020 ESMO Virtual Congress.1,2

At the second interim analysis, the overall blinded independent central review (BICR)-assessed

median PFS in the intent-to-treat (ITT) population was 24.0 months in the brigatinib arm versus 11.0 months in the crizotinib arm (HR, 0.49; 95% CI, 0.35-0.68; P < .0001). The 2-year PFS rates were 48% and 26%, respectively.

Additionally, the intracranial BICR-assessed median PFS was 32.3 months with brigatinib versus 24.0 months with crizotinib (HR, 0.45; 95% CI, 0.29-0.69; P = .0001). The 2-year intracranial PFS rates were 65% and 50%, respectively.

On May 22, 2020, the FDA approved brigatinib for the first-line treatment of patients with ALK-positive metastatic NSCLC, as detected by an FDA-approved test.3

The approval is based on interim findings from the phase 3 ALTA-1L trial, in which brigatinib led to a 51% reduction in the risk of disease progression or death compared with crizotinib in patients with advanced ALK-positive NSCLC who had not received a prior ALK inhibitor.

In the international, open-label, multicenter, ALTA-1L trial, patients with stage IIIB/IV ALK-positive NSCLC who had not received prior treatment with an ALK inhibitor, but could have received 1 prior regimen of chemotherapy in the advanced setting, were randomized to 180 mg of brigatinib once daily (n = 137), with a 7-day lead-in period at 90 mg, or 250 mg of crizotinib twice daily (n = 138). Crossover from the crizotinib arm to receive brigatinib was permitted at BICR-assessed PFS.

The primary end point of the study was BICR-assessed PFS, and secondary end points included objective response rate (ORR) per RECIST v1.1 criteria, intracranial ORR, intracranial PFS, overall survival (OS), safety, and tolerability.

Twenty-nine percent of patients had brain metastases at baseline with comparable pre-enrollment central nervous system (CNS) radiotherapy rates among both cohorts. Overall, 27% of patients had prior chemotherapy in the locally advanced or metastatic setting.

As of the second interim analysis, 55% of patients in the brigatinib arm (n = 75) and 17% of patients in the crizotinib arm (n = 23) remained on study treatment. Just less than half of patients discontinued crizotinib and crossed over to brigatinib (n = 61; 44%).

In patients with brain metastases at baseline, the median PFS was 24 months with brigatinib versus 5.6 months with crizotinib (HR, 0.25; 95% CI, 0.14-0.46; P < .0001). The 2-year PFS rates were 43% and 10%, respectively.

In patients without brain metastases at baseline, the median PFS was 24 months with brigatinib versus 13 months with crizotinib (HR, 0.65; 95% CI, 0.44-0.97; P = .030). The 2-year PFS rates were 50% and 32%, respectively.

Additionally, the BIRC-assessed event-free survival rates favored brigatinib in all landmark analyses in patients with baseline brain metastases.

In patients with any brain metastases at baseline, the median intracranial PFS was 24 months with brigatinib versus 5.6 months with crizotinib (HR, 0.31; 95% CI, 0.17-0.56; P < .0001). The 2-year intracranial PFS rates were 48% and 15%, respectively.

In patients with measurable brain metastases at baseline, the confirmed intracranial ORR was 78% in the brigatinib arm versus 26% in the crizotinib arm (P = .0014). In patients with any brain metastases at baseline, the ORRs were 66% and 16%, respectively (P < .0001).

Moreover, brigatinib led to fewer events and longer median overall and intracranial PFS versus crizotinib in patients with baseline brain metastases, irrespective of prior brain radiotherapy. Although overall and intracranial PFS was improved most with brigatinib versus crizotinib in patients with prior brain radiotherapy, benefit was also observed in patients without prior brain radiotherapy.

The most common sites of BICR-assessed intracranial progression included the frontal lobe, parietal lobe, and cerebellum in both arms.

Patients in the brigatinib arm also experienced sustained improvements in HRQoL, displaying significant delays in time to deterioration in multiple functional and symptom subscales versus crizotinib.

In the ITT population, patients’ EORTC QLQ-C30 global health status (GHS)/QoL score deteriorated in 43.5% of patients in the brigatinib arm versus 53.4% of patients in the crizotinib arm. The median time to deterioration was 26.7 months and 8.3 months, respectively (HR, 0.70; 95% CI, 0.49-1.00; P = .0485).

The time to deterioration across all EORTC QLQ-C30 subscale scores was significantly delayed with brigatinib versus crizotinib; these included physical functioning (HR, 0.67), role functioning (HR, 0.84), emotional functioning (HR, 0.56), cognitive functioning (HR, 0.75), social functioning (HR, 0.59), fatigue (HR, 0.67), nausea and vomiting (HR, 0.55), appetite loss (HR, 0.62), and constipation (HR, 0.52).

Brigatinib also led to a significant delay in time to deterioration in GHS/QoL score in patients with baseline brain metastases, with a median time of 16.6 months versus 4.7 months with crizotinib (HR, 0.54; 95% CI, 0.29-1.00; P = .0415). A numerical delay in time to deterioration in GHS/QoL score was also reported with brigatinib versus crizotinib in patients without brain metastases at baseline, with a median time to deterioration that was not reached with brigatinib versus 10.8 months with crizotinib (HR, 0.81; 95% CI, 0.52-1.26; P = .3284).

The time to deterioration in GHS/QoL score was also delayed in patients who received brigatinib versus crizotinib, regardless of whether they had received prior chemotherapy (HR, 0.76; 95% CI, 0.40-1.43; P = .4016) or not (HR, 0.68; 95% CI, 0.44-1.04; P = .0695); however, the difference in delay between arms was not statistically significant.

A trend toward delayed time to deterioration of GHS/QoL score in brigatinib responders versus brigatinib nonresponders was also reported. The median time to deterioration in GHS/QoL score was not reached in responders versus 7.7 months with nonresponders (HR, 0.53; 95% CI, 0.28-1.02; P = .0588).

References

  1. Rosario Garcia Campelo M, Zhu Y, Lin HM, et al. Health-related quality of life in a phase 3 study of first-line brigatinib vs crizotinib in NSCLC: updated results from ALTA-1L. Presented at 2020 ESMO Congress; September 19-September 21, 2020; Virtual.Abstract 1305P.
  2. Popat S, Kim HR, Ahn MJ, et al. Intracranial activity of brigatinib vs crizotinib: updated results from the ALTA-1L trial. Presented at 2020 ESMO Congress; September 19-September 21, 2020; Virtual. Abstract 1300P.
  3. U.S. FDA approves Takeda’s ALUNBRIG® (brigatinib) as a first-line treatment option for patients diagnosed with rare and serious form of lung cancer. Takeda. May 22, 2020. Accessed September 30, 2020. https://bit.ly/3gc8qk5.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity
View More
Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma
Video

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

Jun 5th 2025 - Jul 12th 2025

online-activity
View More
Medical Crossfire®: The Precision Path for HER2 and TROP2-Targeted Treatments in Non–Small Cell Lung Cancer
Video

Medical Crossfire®: The Precision Path for HER2 and TROP2-Targeted Treatments in Non–Small Cell Lung Cancer

Jun 5th 2025 - Jul 12th 2025

online-activity
View More
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
View More
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
View More
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity
View More
Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma
Video

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

Jun 5th 2025 - Jul 12th 2025

online-activity
View More
Medical Crossfire®: The Precision Path for HER2 and TROP2-Targeted Treatments in Non–Small Cell Lung Cancer
Video

Medical Crossfire®: The Precision Path for HER2 and TROP2-Targeted Treatments in Non–Small Cell Lung Cancer

Jun 5th 2025 - Jul 12th 2025

online-activity
View More
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
View More
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
View More
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity
View More
Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma
Video

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

Jun 5th 2025 - Jul 12th 2025

online-activity
View More
Medical Crossfire®: The Precision Path for HER2 and TROP2-Targeted Treatments in Non–Small Cell Lung Cancer
Video

Medical Crossfire®: The Precision Path for HER2 and TROP2-Targeted Treatments in Non–Small Cell Lung Cancer

Jun 5th 2025 - Jul 12th 2025

online-activity
View More
Related Content
Advertisement
Paolo Ghia, MD, PhD
June 18th 2025

Hematologists Highlight Notable Insights From the 2025 EHA Congress

MedNews Week
December 12th 2024

Delve Into Data With Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen Liu, MD

MDS | Image Credit: © Bipul Kumar - stock.adobe.com
June 17th 2025

Post Hoc Analysis Shows Imetelstat Drives Benefit in RS-Negative, Lower-Risk MDS

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD
October 16th 2024

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD

CAR T-cell therapy in DLBCL |   Image Credit:© Nicat - stock.adobe.com
June 17th 2025

Axi-Cel, Liso-Cel, and Tisa-Cel Show Comparable Real-World Survival Outcomes in DLBCL

CLL/SLL | Image Credit: © Oleksandr - stock.adobe.com
June 16th 2025

Pirtobrutinib Improves Patient-Reported Outcomes in Relapsed/Refractory CLL/SLL

Related Content
Advertisement
Paolo Ghia, MD, PhD
June 18th 2025

Hematologists Highlight Notable Insights From the 2025 EHA Congress

MedNews Week
December 12th 2024

Delve Into Data With Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen Liu, MD

MDS | Image Credit: © Bipul Kumar - stock.adobe.com
June 17th 2025

Post Hoc Analysis Shows Imetelstat Drives Benefit in RS-Negative, Lower-Risk MDS

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD
October 16th 2024

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD

CAR T-cell therapy in DLBCL |   Image Credit:© Nicat - stock.adobe.com
June 17th 2025

Axi-Cel, Liso-Cel, and Tisa-Cel Show Comparable Real-World Survival Outcomes in DLBCL

CLL/SLL | Image Credit: © Oleksandr - stock.adobe.com
June 16th 2025

Pirtobrutinib Improves Patient-Reported Outcomes in Relapsed/Refractory CLL/SLL

Latest Conference Coverage

Hematologists Highlight Notable Insights From the 2025 EHA Congress

Post Hoc Analysis Shows Imetelstat Drives Benefit in RS-Negative, Lower-Risk MDS

Bexobrutideg Is Tolerable and Yields High Response Rates in Relapsed/Refractory Waldenström Macroglobulinemia

Axi-Cel, Liso-Cel, and Tisa-Cel Show Comparable Real-World Survival Outcomes in DLBCL

View More Latest Conference Coverage
Advertise
About OncLive
Editorial Board
MJH Life Sciences brands
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

Download on Apple
© 2025 MJH Life Sciences

All rights reserved.
Home
About Us
News
Contact